MUC1-CTL

MUC1-CTL refers to cytotoxic T lymphocytes (CTLs) engineered or activated to specifically target the tumor-associated antigen **MUC1**, a highly glycosylated type 1 transmembrane mucin overexpressed and aberrantly glycosylated in a wide range of carcinomas, including breast, pancreatic, renal cell, and others[4][5]. MUC1-CTL immunotherapy utilizes CTLs that recognize MUC1-derived peptide epitopes presented by major histocompatibility complex class I molecules on tumor cells, leading to **tumor cell lysis via antigen-specific cytotoxicity**[4]. Mechanistically, these CTLs recognize specific sequences (such as tandem repeats) from MUC1 and, upon activation, induce apoptosis of tumor cells expressing MUC1. The approach is intended to overcome immune evasion strategies by tumors, especially where MUC1 is implicated in immune suppression, chemoresistance, and metastatic progression[1][2][4]. Preclinical studies have shown that these CTLs can selectively kill MUC1-expressing cancer cells but spare normal cells, supporting the principle of targeted immunotherapy[4].

Brand names

MUC1-CTLMUC-1-CTLMUC 1-CTL

Other names

MUC1-CTLMUC-1-CTLMUC 1-CTL